Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

What's Behind Globus Medical's Market-Beating Q3 Results

By Keith Speights - Nov 7, 2019 at 6:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The medical device maker yet again topped analysts' estimates. Here's how.

Globus Medical ( GMED 0.75% ) has delivered solid results so far in 2019, thanks in large part to the company's products used in spine surgical procedures. This performance led to Globus stock jumping nearly 23% year to date.

The company announced its third-quarter results after the market closed on Wednesday. Globus Medical kept the momentum going with a solid quarter yet again. Here are the highlights from its Q3 update.

Doctor putting his hands on a man's back with an image of his spine appear on the patient's shirt.

Image source: Getty Images.

By the numbers

Globus Medical reported third-quarter revenue of $196.2 million, a 16% year-over-year jump. This figure easily topped the average analysts' revenue estimate of $185.9 million.

The company announced net income in the third quarter of $38.3 million, or $0.38 per share, based on generally accepted accounting principles (GAAP). This compared to $35.2 million, or $0.35 per share, in the same period in 2018.

Globus posted adjusted non-GAAP net income in the third quarter of $0.43 per share, a year-over-year increase of 10%. The company's adjusted earnings per share (EPS) also narrowly beat the consensus analysts' estimate of $0.42 per share.

Behind the numbers

Globus Medical CEO Dave Demski referred to his company's performance in Q3 as "outstanding." The company's musculoskeletal solutions business is its biggest moneymaker, generating nearly 93% of total sales. This unit had another solid quarter, with sales increasing 11.8% year over year to $182.3 million. Demski attributed this success to "competitive recruiting, new product introductions, and implant pull through from ExcelsiusGPS installations." ExcelciusGPS is the company's surgical robot system.

The company's enabling technologies business pulled in $13.9 million in the third quarter. While this was much lower than Globus Medical's musculoskeletal solutions unit, it reflected a 125% jump from sales in the prior-year period.

Demski said that Globus delivered "industry-leading profitability" in the third quarter. The company's earnings growth stemmed primarily from the trickle-down impact of its higher revenue. However, spending increased a little faster than revenue did, with operating expenses rising nearly 17% year over year.

Looking ahead

Investing in healthcare stocks like Globus Medical requires looking at the future more than the past. The good news is that Globus' future appears to be a bright one.

Globus Medical expects that revenue for full-year 2019 will be between $775 million to $783 million, up from its previous guidance of $770 million to $775 million. The company anticipates non-GAAP EPS of $1.72, in line with Wall Street's full-year estimate.

Investors will also want to keep their eyes on Globus' activity related to its acquisition earlier this year of StelKast, a small maker of total joint arthroplasty systems. This acquisition should boost Globus Medical's robotics business but probably won't have a significant impact until sometime next year.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Globus Medical, Inc. Stock Quote
Globus Medical, Inc.
GMED
$63.09 (0.75%) $0.47

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
656%
 
S&P 500 Returns
144%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.